One-month humoral response following two or three doses of mRNA Covid-19 vaccines as primary vaccination in specific populations in France: first results from the ANRS0001S COV-POPART cohort - Inria - Institut national de recherche en sciences et technologies du numérique Access content directly
Journal Articles Clinical Microbiology and Infection Year : 2023

One-month humoral response following two or three doses of mRNA Covid-19 vaccines as primary vaccination in specific populations in France: first results from the ANRS0001S COV-POPART cohort

1 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
2 VBIC - Virulence Bactérienne et Infections Chroniques
3 F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC)
4 SISTM - Statistics In System biology and Translational Medicine
5 BPH - Bordeaux population health
6 CHU Bordeaux
7 CIC Bordeaux
8 ISPED - Institut de Santé Publique, d'Epidémiologie et de Développement
9 UVE - Unité des Virus Emergents
10 IHU Marseille - Institut Hospitalier Universitaire Méditerranée Infection
11 CHU Pitié-Salpêtrière [AP-HP]
12 SU - Sorbonne Université
13 Centre Léon Bérard [Lyon]
14 UCBL - Université Claude Bernard Lyon 1
15 UNICANCER
16 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
17 IGF - Institut de Génomique Fonctionnelle
18 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
19 Université de Lyon
20 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
21 CIC - Centre d'Investigation Clinique [Rennes]
22 VRI - Vaccine Research Institute [Créteil, France]
23 Hôpital Henri Mondor
24 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
25 UM - Université de Montpellier
26 CIMI - Centre d'Immunologie et des Maladies Infectieuses
27 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
28 Hôpital Cochin [AP-HP]
29 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
30 Hôpital Haut-Lévêque [CHU Bordeaux]
31 UB - Université de Bordeaux
32 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
33 FIRE - Fédération Île-de-France de Recherche sur l'Environnement
34 UPCité - Université Paris Cité
35 Essais Thérapeutiques et Maladies Infectieuses
36 ANRS - MIE - ANRS - Maladies infectieuses émergentes
37 Hôpital Edouard Herriot [CHU - HCL]
38 HEGP - Hôpital Européen Georges Pompidou [APHP]
39 CIC 1417 - CIC Cochin Pasteur

Abstract

Objectives - We aimed to investigate the 1-month humoral response to two or three doses of a messenger RNA coronavirus disease 2019 (COVID-19) vaccine as a primary vaccination regimen in specific populations compared with that in healthy adults. Methods - Agence Nationale Recherche contre le Sida (ANRS)0001S-COV-POPART (NCT04824651) is a French nation-wide, multi-centre, prospective, observational cohort study assessing the immune response to COVID-19 vaccines routinely administered to 11 sub-groups of patients with chronic conditions and two control groups. Patients and controls who received at least two vaccine doses and whose results 1 month after the second dose were available were included. The humoral response was assessed 1 month after the first, second and third doses (if applicable) based on the percentage of responders (positive for anti-Spike severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] IgG antibodies), geometric means of anti-Spike SARS-CoV-2 IgG antibodies (enzyme-linked immunosorbent assay) and proportion of participants with anti-SARS-CoV-2-specific neutralizing antibodies (in vitro neutralization assay for the original SARS-CoV-2 strain). All analyses were centralized. Results - We included 4091 participants in this analysis: 2979 participants from specific sub-populations and 1112 controls. Only 522 (17.5%) participants from the specific populations received three doses as a primary vaccination regimen. Patients living with human immunodeficiency virus, cancer and diabetes had high percentages of responders after two doses, whereas patients with solid organ transplants, allogeneic hematopoietic stem cell transplants and hypogammaglobulinaemia had the lowest percentage of responders (35.9% [95% CI, 29.2-43.0], 57.4% [95% CI, 48.1-66.3] and 77.1% [95% CI, 65.6-86.3], respectively). In those who received the third dose, the percentage of responders reached 54.2% (95% CI, 42.9-65.2) (vs. 32.3% [95% CI, 16.7-51.4] after 2 doses) among those with solid organ transplants and 73.9% (95% CI, 58.9-85.7) (vs. 56.1% [95% CI, 46.2-65.7] after 2 doses) among those with hematopoietic stem cell transplants. Similar results were found with anti-SARS-CoV-2-specific neutralizing antibodies. Conclusions - A lower humoral response to COVID-19 vaccines was observed in the specific populations compared with that in the controls. The third dose of this vaccine in the primary regimen had a positive effect on the percentages of patients who developed anti-Spike IgG antibodies and specific neutralizing antibodies.
Fichier principal
Vignette du fichier
2022 Loubet et al., One month.pdf (29.96 Mo) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03822592 , version 1 (08-11-2022)

Identifiers

Cite

Paul Loubet, Linda Wittkop, Laetitia Ninove, Mathieu Chalouni, Benoit Barrou, et al.. One-month humoral response following two or three doses of mRNA Covid-19 vaccines as primary vaccination in specific populations in France: first results from the ANRS0001S COV-POPART cohort. Clinical Microbiology and Infection, 2023, 29 (3), pp.388.e1-388.e8. ⟨10.1016/j.cmi.2022.10.009⟩. ⟨hal-03822592⟩
294 View
9 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More